{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:30:21Z","timestamp":1784759421043,"version":"3.55.0"},"reference-count":128,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by the increased production of monoclonal immunoglobulin. Patients with MM are at high risk of suffering from disease-related complications. Osteolytic bone disease is one of the most common disease-related complications, resulting in chronic pain and skeletal pathologies that contribute significantly to high morbidity and mortality rates among MM patients. In addition to standard anti-MM therapy, management of disease-related sequelae is integral to improving quality of life in MM patients. Bisphosphates have long been the mainstay treatment for patients with myeloma bone disease (MBD) due to their ability to reduce the incidence of skeletal-related adverse events. However, in recent years, a deeper understanding of the complex biology and pathophysiology associated with myeloma bone disease has led to the development of novel therapies that have the potential to improve MM patient management and outcomes. This narrative review uses the most recent extant publications to review all such advancements. It aims to summarize evidence-based strategies for the management of myeloma bone disease and therapy-associated adverse events whilst highlighting current guidelines on optimal bisphosphonate use and providing an overview of promising new agents currently in clinical development.<\/jats:p>","DOI":"10.3390\/cancers17132166","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:18:36Z","timestamp":1751264316000},"page":"2166","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in Supportive Care for Multiple Myeloma-Related Bone Disease\u2014A Review"],"prefix":"10.3390","volume":"17","author":[{"given":"Saadia","family":"Abbas","sequence":"first","affiliation":[{"name":"Medical College, Aga Khan University, Karachi 74800, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9852-8935","authenticated-orcid":false,"given":"Haleema Sadia","family":"Adil","sequence":"additional","affiliation":[{"name":"University College London Medical School, London WC1E 6DE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2265","authenticated-orcid":false,"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janita","family":"Basit","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Arul","sequence":"additional","affiliation":[{"name":"Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-4437","authenticated-orcid":false,"given":"Muhammad Hamza","family":"Habib","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s11764-022-01184-1","article-title":"Racial disparities in follow-up care of early-stage lung cancer survivors","volume":"17","author":"Malhotra","year":"2023","journal-title":"J. Cancer Surviv. Res. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Coluzzi, F., Rolke, R., and Mercadante, S. (2019). Pain Management in Patients with Multiple Myeloma: An Update. Cancers, 11.","DOI":"10.3390\/cancers11122037"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"CGM.S16817","DOI":"10.4137\/CGM.S16817","article-title":"Bone disease in multiple myeloma: Pathophysiology and management","volume":"7","author":"Hameed","year":"2014","journal-title":"Cancer Growth Metastasis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5435\/00124635-201107000-00004","article-title":"Multiple myeloma: Diagnosis and orthopaedic implications","volume":"19","author":"Scharschmidt","year":"2011","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00520-014-2552-1","article-title":"Treatment-related symptom management in patients with multiple myeloma: A review","volume":"23","author":"Colson","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Santoni, A., Simoncelli, M., Franceschini, M., Ciofini, S., Fredducci, S., Caroni, F., Sammartano, V., Bocchia, M., and Gozzetti, A. (2022). Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI. J. Pers. Med., 12.","DOI":"10.3390\/jpm12111885"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: How? When?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: Imaging \u201cearly myeloma\u201d","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","first-page":"76","article-title":"Multiple myeloma and bone disease: Pathogenesis and current therapeutic approaches","volume":"14","author":"Papadopoulou","year":"2010","journal-title":"Hippokratia"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ayati, B.P., Edwards, C.M., Webb, G.F., and Wikswo, J.P. (2010). A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. Biol. Direct, 5.","DOI":"10.1186\/1745-6150-5-28"},{"key":"ref_12","first-page":"271","article-title":"Mechanisms of bone resorption in myeloma","volume":"3","author":"Roodman","year":"2003","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_13","first-page":"699","article-title":"[Mechanisms of myeloma-induced bone disease]","volume":"26","author":"Abe","year":"2016","journal-title":"Clin. Calcium"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2007-10-120253","article-title":"Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10245330512331389782","article-title":"Myeloma bone disease","volume":"10","author":"Sezer","year":"2005","journal-title":"Hematology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3892\/etm.2021.10764","article-title":"Modern markers for evaluating bone disease in multiple myeloma (Review)","volume":"22","author":"Pop","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/leu.2010.173","article-title":"The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.blre.2004.06.001","article-title":"The role of markers of bone remodeling in multiple myeloma","volume":"19","author":"Terpos","year":"2005","journal-title":"Blood Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2141.2003.04050.x","article-title":"Comparison of five biochemical markers of bone resorption in multiple myeloma: Elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy","volume":"120","author":"Abildgaard","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2141.2000.01960.x","article-title":"Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients","volume":"109","author":"Fonseca","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2015.05.001","article-title":"The prognostic role of bone turnover markers in multiple myeloma patients: The impact of their assay. A systematic review and meta-analysis","volume":"96","author":"Pecoraro","year":"2015","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma\u2013Related Bone Disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_24","first-page":"311","article-title":"Bisphosphonates for osteoporosis","volume":"363","author":"Narusawa","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"ref_28","first-page":"1465","article-title":"Bisphosphonates in multiple myeloma: An updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00198-018-4787-z","article-title":"Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance","volume":"30","author":"Stein","year":"2019","journal-title":"Osteoporos. Int"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Bonello, F., Grasso, M., D\u2019agostino, M., Celeghini, I., Castellino, A., Boccadoro, M., and Bringhen, S. (2020). The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010020"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1078-0432.CCR-15-1864","article-title":"Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study","volume":"22","author":"Raje","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs. 4 Weeks in Women with Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial-PubMed","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-024-01046-2","article-title":"In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease","volume":"14","author":"Lund","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: Recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet. Oncol."},{"key":"ref_43","first-page":"627","article-title":"Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases","volume":"16","author":"Dougall","year":"2006","journal-title":"Clin. Calcium"},{"key":"ref_44","first-page":"370","article-title":"Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis","volume":"33","author":"Bruhn","year":"2010","journal-title":"Med. Monatsschrift F\u00fcr Pharm."},{"key":"ref_45","first-page":"331","article-title":"Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients","volume":"7","author":"Yee","year":"2012","journal-title":"Clin. Interv. Aging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bjh.17256","article-title":"Controversies in the use of new bone-modifying therapies in multiple myeloma","volume":"193","author":"Terpos","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: From biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance","volume":"48","author":"Bamias","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","article-title":"Renal failure in multiple myeloma. Pathogenesis and prognostic implications","volume":"150","author":"Alexanian","year":"1990","journal-title":"Arch. Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.ackd.2013.08.009","article-title":"Myeloma-related kidney disease","volume":"21","author":"Leung","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17474086.2018.1531702","article-title":"Management of multiple myeloma bone disease: Impact of treatment on renal function","volume":"11","author":"Kanellias","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cam4.749","article-title":"Prevalence of hypercalcemia among cancer patients in the United States","volume":"5","author":"Gastanaga","year":"2016","journal-title":"Cancer Med."},{"key":"ref_60","first-page":"539","article-title":"Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: A randomized multicentric comparison to pamidronate","volume":"11","author":"Pecherstorfer","year":"2003","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.clml.2014.07.005","article-title":"Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction","volume":"14","author":"Cicci","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.3390\/curroncol30030248","article-title":"Vitamin D and Multiple Myeloma: A Scoping Review","volume":"30","author":"Mirhosseini","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11899-017-0370-5","article-title":"An Evidence-Based Approach to Myeloma Bone Disease","volume":"12","author":"Bingham","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2141.2008.07214.x","article-title":"Prevalence and significance of vitamin D deficiency in multiple myeloma patients","volume":"142","author":"Badros","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/0973-1482.63570","article-title":"Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review","volume":"6","author":"Weide","year":"2010","journal-title":"J. Cancer Res. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"502","DOI":"10.6004\/jnccn.2014.0055","article-title":"Advances in supportive care for multiple myeloma","volume":"12","author":"Raje","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","article-title":"Natural history of osteonecrosis of the jaw in patients with multiple myeloma","volume":"26","author":"Badros","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_70","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"ref_71","first-page":"e30485","article-title":"The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis","volume":"14","author":"Aboalela","year":"2022","journal-title":"Cureus"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus-PubMed","volume":"30I","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-Related Osteonecrosis of the Jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/njms.NJMS_236_20","article-title":"Medication-related osteonecrosis of the jaw: An update","volume":"13","author":"Bansal","year":"2022","journal-title":"Natl. J. Maxillofac. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/SPC.0000000000000467","article-title":"Mechanisms and treatment of bone pain in multiple myeloma","volume":"13","author":"Davies","year":"2019","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_76","first-page":"284","article-title":"WHO Analgesic Ladder","volume":"38","author":"Anekar","year":"2024","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"Snowden","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.18060\/27180","article-title":"Under-treatment of Pain in Black Patients: A Historical Overview, Case-based Analysis, and Legalities as Explored Through the Tenets of Critical Race Theory","volume":"20","author":"Habib","year":"2023","journal-title":"Indiana Health Law. Rev."},{"key":"ref_79","unstructured":"(2025, February 20). Neuropathic Pain in Adults: Pharmacological Management in Non-Specialist Settings, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK552848\/pdf\/Bookshelf_NBK552848.pdf."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1089\/jpm.2021.0373","article-title":"Urinary Incontinence in Palliative Care Settings: Part 2: Management #426","volume":"24","author":"Habib","year":"2021","journal-title":"J. Palliat. Med."},{"key":"ref_81","unstructured":"(2025, February 05). Peripheral Neuropathy-Treatment-NHS. Available online: https:\/\/www.nhs.uk\/conditions\/peripheral-neuropathy\/treatment\/."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13014-015-0374-z","article-title":"Effects of Radiotherapy in the treatment of multiple myeloma: A retrospective analysis of a Single Institution","volume":"10","author":"Matuschek","year":"2015","journal-title":"Radiat. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Rudzianskiene, M., Rudzianskas, V., Dambrauskiene, R., and Gerbutavicius, R. (2018). The Role of Radiology and Radiotherapy for Multiple Myeloma. Update on Multiple Myeloma, IntechOpen.","DOI":"10.5772\/intechopen.75397"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"100729","DOI":"10.1016\/j.adro.2021.100729","article-title":"Effective Pain Control with Very Low Dose Palliative Radiation Therapy for Patients with Multiple Myeloma with Uncomplicated Osseous Lesions-PubMed","volume":"6","author":"Price","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"100668","DOI":"10.1016\/j.jbo.2025.100668","article-title":"Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives","volume":"51","author":"Lungu","year":"2025","journal-title":"J. Bone Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2023.2173175","article-title":"Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: Current challenges and scopes of improvement-PubMed","volume":"23","author":"Colciago","year":"2023","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3174\/ajnr.A3622","article-title":"Vertebral augmentation in patients with multiple myeloma: A pooled analysis of published case series","volume":"35","author":"Khan","year":"2014","journal-title":"AJNR. Am. J. Neuroradiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.21037\/apm-23-433","article-title":"Interventional pain management in cancer patients-a scoping review","volume":"12","author":"Habib","year":"2023","journal-title":"Ann. Palliat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-019-0187-7","article-title":"The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: A consensus statement from the International Myeloma Working Group (IMWG)","volume":"9","author":"Kyriakou","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.sult.2005.02.003","article-title":"Complications of percutaneous vertebroplasty and their prevention","volume":"26","author":"Laredo","year":"2005","journal-title":"Semin. Ultrasound CT MR"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1007\/s00330-016-4703-x","article-title":"Percutaneous low-pressure bone stenting to control cement deposition in extensive lytic lesions","volume":"27","author":"Cornelis","year":"2017","journal-title":"Eur. Radiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/02841850600570425","article-title":"Percutaneous balloon kyphoplasty in the treatment of pathological vertebral body fracture and deformity in multiple myeloma: A one-year follow-up","volume":"47","author":"Pflugmacher","year":"2006","journal-title":"Acta Radiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3174\/ajnr.A0918","article-title":"Vertebroplasty in Multiple Myeloma: Outcomes in a Large Patient Series","volume":"29","author":"McDonald","year":"2008","journal-title":"Am. J. Neuroradiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00270-011-0111-4","article-title":"Percutaneous Vertebroplasty in Multiple Myeloma: Prospective Long-Term Follow-Up in 106 Consecutive Patients","volume":"35","author":"Anselmetti","year":"2011","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.crad.2010.09.011","article-title":"Safety and efficacy of percutaneous vertebroplasty in malignancy: A systematic review","volume":"66","author":"Chew","year":"2011","journal-title":"Clin. Radiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13013-016-0107-6","article-title":"Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma","volume":"11","author":"Audat","year":"2016","journal-title":"Scoliosis"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3340\/jkns.2013.54.2.151","article-title":"Multiple Myeloma and Epidural Spinal Cord Compression: Case Presentation and a Spine Surgeon\u2019s Perspective","volume":"54","author":"Ha","year":"2013","journal-title":"J. Korean Neurosurg. Soc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.ijrobp.2005.10.018","article-title":"Short-course radiotherapy is not optimal for spinal cord compression due to myeloma","volume":"64","author":"Rades","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1089\/jpm.2021.0372","article-title":"Urinary Incontinence in Palliative Care Settings: Part 1: Etiology and Workup #425","volume":"24","author":"Habib","year":"2021","journal-title":"J. Palliat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1089\/jpm.2021.0370","article-title":"Fecal Incontinence in Palliative Care Settings #424-PubMed","volume":"24","author":"Habib","year":"2021","journal-title":"J. Palliat. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/jpm.2023.0545","article-title":"Top Ten Tips Palliative Care Clinicians Should Know About Physical Therapy, Occupational Therapy, and Speech Language Pathology","volume":"27","author":"Habib","year":"2024","journal-title":"J. Palliat. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Lan, Z., Lv, Z., Zuo, W., and Xiao, Y. (2023). From bench to bedside: The promise of sotatercept in hematologic disorders. Biomed. Pharmacother., 165.","DOI":"10.1016\/j.biopha.2023.115239"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.metabol.2017.11.012","article-title":"Biology and treatment of myeloma related bone disease","volume":"80","author":"Terpos","year":"2018","journal-title":"Metab. Clin. Exp."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Gau, Y.-C., Yeh, T.-j., Hsu, C.-M., Hsiao, S.Y., and Hsiao, H.-H. (2022). Pathogenesis and Treatment of Myeloma-Related Bone Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063112"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_109","unstructured":"(2025, February 05). Study Details|Sotatercept (ACE-011) with Lenalidomide or Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma|ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01562405."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/blood-2018-10-879247","article-title":"Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with \u03b2-thalassemia-PubMed","volume":"133","author":"Piga","year":"2019","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e882049a","DOI":"10.1097\/01.HS9.0000972748.88204.9a","article-title":"P1466: Effect of Luspatercept on Bone Mineral Density in Patients with Beta-Thalassemia Enrolled in the Phase 3 Believe Trial","volume":"7","author":"Coates","year":"2023","journal-title":"HemaSphere"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1038\/s41375-022-01702-1","article-title":"Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice","volume":"36","author":"Weidner","year":"2022","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Mukkamalla, S.K.R., and Malipeddi, D. (2021). Myeloma Bone Disease: A Comprehensive Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126208"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V120.21.331.331","article-title":"Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression","volume":"120","author":"Munshi","year":"2012","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert. Rev. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Toscani, D., Bolzoni, M., Ferretti, M., Palumbo, C., and Giuliani, N. (2018). Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02467"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease","volume":"31","author":"Eda","year":"2016","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e1268","DOI":"10.1093\/oncolo\/oyad188","article-title":"A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects with Cancer Pain Due to Bone Metastasis","volume":"28","author":"Fallon","year":"2023","journal-title":"Oncologist"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.17131","article-title":"Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: Results from the Connect\u00ae MM Registry","volume":"193","author":"Abonour","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","article-title":"Quality of life in multiple myeloma: Considerations and recommendations","volume":"12","author":"Seitzler","year":"2019","journal-title":"Expert. Rev. Hematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1089\/jpm.2021.0102","article-title":"Functional Status Assessment in Serious Illness #416","volume":"24","author":"Arnold","year":"2021","journal-title":"J. Palliat. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_126","first-page":"238","article-title":"Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia: A Randomized Clinical Trial","volume":"7","author":"LeBlanc","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Gerov, V., Gerova, D., Micheva, I., Nikolova, M., Mihaylova, G., and Galunska, B. (2023). Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134440"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2166\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:59:54Z","timestamp":1760032794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":128,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17132166"],"URL":"https:\/\/doi.org\/10.3390\/cancers17132166","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}